Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C53H87NO19 |
Molecular Weight | 1042.2532 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]2[C@@H](C)O[C@@]([H])(O[C@H]3[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@H](CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC)[C@@H](CC)OC(=O)C[C@@H](OC(C)=O)[C@@H]3C)[C@H](O)[C@H]2N(C)C
InChI
InChIKey=KCJJINQANFZSAM-HZDSEHBESA-N
InChI=1S/C53H87NO19/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3/b18-17+,28-22+/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-/m1/s1
DescriptionSources: https://www.ema.europa.eu/en/documents/product-information/aivlosin-epar-product-information_en.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19767637 | https://www.ncbi.nlm.nih.gov/pubmed/25185108 | https://www.ncbi.nlm.nih.gov/pubmed/29696149http://www.ecoanimalhealth.com/us/US04PIM-6A5%20Aivlosin%20Water%20soluble%20granules%20Pack%20Insert%20-%20USA%20-%20Pigs.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26392896
Sources: https://www.ema.europa.eu/en/documents/product-information/aivlosin-epar-product-information_en.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19767637 | https://www.ncbi.nlm.nih.gov/pubmed/25185108 | https://www.ncbi.nlm.nih.gov/pubmed/29696149http://www.ecoanimalhealth.com/us/US04PIM-6A5%20Aivlosin%20Water%20soluble%20granules%20Pack%20Insert%20-%20USA%20-%20Pigs.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26392896
Tylvalosin (TVS) is a third-generation macrolide drug used for prophylaxis and treatment of mycoplasma. Tylvalosin, the active ingredient of Aivlosin
625 mg/g Water Soluble Granules (ECO
Animal Health, UK), is a modern macrolide
that has shown its effectiveness in the control
of porcine proliferative enteropathy, EP and swine dysentery. Aivlosin is indicated for the control of porcine proliferative enteropathy (PPE)
associated with Lawsonia intracellularis infection in
groups of swine in buildings experiencing an outbreak
of PPE. Tylvalosin tartrate is a macrolide antibiotic that has antibacterial activity against Gram-positive, some
Gram-negative organisms and mycoplasma. It acts by inhibiting protein synthesis in the bacteria cell.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AIVLOSIN Approved UseControl of porcine proliferative enteropathy (PPE)
associated with Lawsonia intracellularis infection in
groups of swine in buildings experiencing an outbreak
of PPE. Launch Date2012 |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro activity of tylvalosin against Spanish field strains of Mycoplasma hyopneumoniae. | 2014 Nov 29 |
|
Use of tylvalosin in the control of porcine enzootic pneumonia. | 2015 |
|
Antibiotic susceptibility profiles of Mycoplasma sp. 1220 strains isolated from geese in Hungary. | 2016 Aug 19 |
|
Antimicrobial susceptibility of Brachyspira hyodysenteriae in Switzerland. | 2016 Jun |
Patents
Sample Use Guides
Control of porcine proliferative enteropathy: 50 ppm tylvalosin in drinking water for five consecutive
days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27543140
Tylvalosin (MIC50 0.5 ug/ml) was found to be the most effective drug against M. sp. 1220.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.2645
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
WHO-VATC |
QJ01FA92
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
CFR |
21 CFR 558.633
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
CFR |
21 CFR 556.748
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
||
|
NCI_THESAURUS |
C254
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9T02S42WQO
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
6441094
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
264-132-2
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
8533
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
1368469
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID901016510
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
9T02S42WQO
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
DB11554
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103834
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
UU-49
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
63409-12-1
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
300000023783
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
C545430
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
C152787
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY | |||
|
m11759
Created by
admin on Fri Dec 15 16:24:06 GMT 2023 , Edited by admin on Fri Dec 15 16:24:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY